- Home
- MNSB vs UNCY Comparison
MNSB vs UNCY Comparison
Compare MNSB & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | UNCY |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNSB | UNCY |
|---|---|---|
| Price | $20.53 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 33.3K | ★ 503.8K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,367,000.00 | N/A |
| Revenue This Year | $21.22 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $15.00 | $3.71 |
| 52 Week High | $22.98 | $11.00 |
Technical Indicators
Market Signals| Indicator | MNSB | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 62.26 |
| Support Level | $19.77 | $6.01 |
| Resistance Level | $21.45 | $7.19 |
| Average True Range (ATR) | 0.58 | 0.47 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 56.28 | 85.89 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.